Heath Devin Skinner, MD, PhD, Hillman Cancer Center, Pittsburgh, PA, discusses the advances and future of head and neck cancer treatment. Predicting the response to immunotherapy has involved PD-L1 and tumor mutational burden in the past. The future remains complex with considerations including types of immunotherapy and sites of disease. Additional studies are required to answer outstanding questions in the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
